MTOR and neoplasm: The mTOR catalytic kinase inhibitors that target both mTORC1 and mTORC2 or dual mTOR/PI3K inhibitors are predicted to show greater clinical efficacy than rapalogs for the treatment of LKB1 mutant tumours (Apsel et al, 2008; Maira et al, 2008; Feldman et al, 2009).